Try our beta test site
5 studies found for:    Open Studies | Lymphoma OR CLL | BAY 80-6946
Show Display Options
Rank Status Study
1 Recruiting Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL
Condition: Lymphoma Non-Hodgkin
Intervention: Drug: Copanlisib (BAY80-6946)
2 Recruiting Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
Condition: Lymphoma,Non-Hodgkin
Interventions: Drug: Copanlisib (BAY 80-6946);   Drug: Placebo;   Drug: Rituximab
3 Not yet recruiting Copanlisib and Gemcitabine in Relapsed/Refractory PTCL
Condition: Mature T-Cell and NK-Cell Neoplasm
Interventions: Drug: Copanlisib;   Drug: Gemcitabine
4 Recruiting Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Copanlisib (BAY 80-6946);   Drug: Placebo;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Bendamustine;   Drug: Prednisone
5 Recruiting Phase III Copanlisib in Rituximab-refractory iNHL
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: BAY No. 80 6946;   Drug: Placebo

Study has passed its completion date and status has not been verified in more than two years.